CPF Applauds Two FDA Approvals Announced Today for First Drugs for Idiopathic Pulmonary Fibrosis

October 16, 2014 12:52 AM

3 0

CPF Applauds Two FDA Approvals Announced Today for First Drugs for Idiopathic Pulmonary Fibrosis

CULVER CITY, CALIF., Oct. 15, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) applauds the two U.S. Food and Drug Administration (FDA) approvals announced today for Idiopathic Pulmonary Fibrosis (IPF), the first drugs approved for the disease in the United States.

The CPF, representing tens of thousands of Idiopathic Pulmonary Fibrosis (IPF) patients is sharing the news with the patient and research community that FDA approved InterMune's Esbrriet (pirfenidone) and Boehringer Ingelheim's Ofev (nintedanib) for Idiopathic Pulmonary Fibrosis (IPF).

Read more

To category page

Loading...